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commonly associated with confusion in the elderly. Either
of these factors areplausible explanations forthe confusion
experienced by this patient.
In summary, this patient with known diverticular disease
presentedwithafebrileepisodethatrespondedtoantibiotic
treatment. The authors noted the expected radio-opaque
appearance of lanthanum in the gastrointestinal tract and
plasma lanthanum levels within the range observed in piv-
otal clinical trials. Neither finding has been convincingly
linked to the patient’s presentation; therefore, there are no
grounds for revising the benefit–risk profile for LC.
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Reply
In response to Dr Smyth’s letter to the editor, we would
like to remind readers that lanthanum carbonate has indeed
shown its efficacy, but that many safety concerns remain
unsolved. We would like to draw attention to two main
points brought out in our case report:
1. Gastro-intestinal effects: Lanthanum has been shown to
induce a number of gastrointestinal effects [1].
Patients with acute peptic ulcer, ulcerative colitis, Crohn
disease or bowel obstruction were not included in the
pivotal FOSRENOL(R) study, its 6-year follow-up re-
port [2] or in Finn’s work [3]. Therefore, caution should
be exercised in patients with these conditions [4]. There
was more withdrawal in patients treated with lanthanum
mainly attributable to digestive disorders in these studies.
Our patient had previous digestive disorders and therefore
should be considered a high-risk patient for digestive side
effects.
In our patient, the plasmatic lanthanum level was
2.13 µg/l. In the public assessment report [5], the mean
concentration for long-term ingestion of 3 g lanthanum/day
ranges from 0.5 to 0.6 ng/ml. There was no significant dose
or time effect on treatment. Altman’s study reported the
same mean plasmatic value—0.3 ng/ml—but a wide range
(0.0–3.1 ng/ml). More information would be required to
explain this difference.
It has been shown that the tissue concentration is higher
thantheplasmaconcentrationsowecannotassumethatlan-
thanum is not nontoxic. Tissue accumulation is seen partic-
ularly in the gastro-intestinal tract, lymphoreticular system,
bone, liver and spleen [5]. Recently, Davis and Jerrold re-
ported the detection of lanthanum deposits in a mesenteric
lymph node in a patient 3 years after exposure [6].
The degree of digestive absorption has not been evalu-
ated, nor has the excretion of the unabsorbed dose of lan-
thanum in the faeces been demonstrated in humans [5,7].
ThetwoFDAreviewersformarketapprovaloflanthanum
(Drs Pelayo and Oluferni [1]) made a negative recommen-
dation because of the gastro-intestinal effects and the un-
known accumulation and elimination of the product, which
presented ‘a real risk of malnutrition and additional injury
in this population’. They stated that it can be ‘unacceptably
toxic’.Thesponsorwasinchargeofprovidingproofonthis
point but was unable to do so.
2. The effects on the central nervous system: a number of
animal studies indicate significant brain exposure [8].




It is known that when it passes the blood–brain barrier in
animals, it can be toxic to the nervous system and cogni-
tion [11,12]. In healthy rats, Damment et al. [13] showed
that the lanthanum brain concentration found is considered
contamination.
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Thereisinsufficientevidencetoconcludethatlanthanum
cannot cross the blood–brain barrier in healthy or uraemic
patients, not to mention infected haemodialysed patients.
Many publications agree that further investigation and
more time are needed before it can be firmly concluded
that the tissue accumulation is nontoxic, with no severe
adverse effects [14].
TheTransparencyCommitteeoftheFrenchNationalAu-
thority for Health (Haute Autorit´ e de Sant´ e) has stated that
safe long-term use of lanthanum is not established given
that it accumulates in bone, brain and heart.
We fully agree with Smith and Pratt that the benefice-
risk ratio need not to be revised based on our case re-
port alone. However the nephrological community needs
to be reminded that a product’s safety, especially in dialy-
sis patients, is the cornerstone of patient care. We merely
emphasize that this medication should not be used in the
case of inflammatory or gastro-intestinal disorders since
none of the studies conducted to date have included pa-
tients with these pathologies [1–3]. In addition, the product
label clearly states that the product should not be adminis-
tered to these patients [5,15]. Our article is a reminder that
prescription of this medication is restricted and a warning
that previously reported adverse effects may occur.
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Prescribing peritoneal dialysis in each patient with
uremic toxins as the treatment marker
Sir,
Vilar demonstrated that residual renal function (RPF) is
important not only in PD, but also in HD. All these benefits
occur despite those with RRF having a lower delivered HD
dose [1].
We examined the number of PD bag exchanges in 79
incident PD patients with RPF at our hospital from January
2006 to June 2009. The result was that one bag (2 L) was
exchanged in 2% of the patients, two bags in 44%, three
bags in 46% and four bags in 8%. We increased the number
ofbagexchanges inpatientswhohaduncontrolledfluidac-
cumulationandpoorsoluteremoval(e.g.,β2-microglobulin
(β2 MG)>35 pg/ml) or EPO-resistant anaemia. Among the
37 incident PD patients in whom one to two bags were ex-
changed, 1 died and 2 received renal transplants. Of the 28
patients who continued PD for more than 1 year, 19 (68%)
received continuous PD treatment with exchange of one to
two bags (Figure 1). In these patients, RPF maintained, al-
though urine volume decreased from 1440 ± 364ml/day to
1020 ± 589 ml/day slightly during 1 year.
At the end of 2006, nearly 320000 ESRD patients were
receiving haemodialysis therapy, 25438 were being treated
with peritoneal dialysis (PD) in the United States and they
are rapidly aging. We should consider medical costs and
QOL when performing PD treatment. Increasing the PD
solution volume was recommended in the NKF-K/DOQI
and other guidelines before 2000, because these were be-
lievedtoimprovetheprognosis.However,Loetal.reported
thatitisnotsolutionvolumebutresidualrenalfunctionthat
affects the prognosis [2]. Therefore, performing PD with a
similar solution volume in all patients is not rational, so we
investigated low-volume PD in this study.
The solution volume used to be considered to be impor-
tantinPDtreatment, butitseemsthatweshouldchange the
therapeutic strategy to target accumulation of uraemic tox-
ins such as β2 MG and control accumulation of fluid, which
have also been shown to be associated with the prognosis in
patients on HD. We reported that accumulation of uraemic
toxins such as β2 MG leads to peritoneal injury or EPS [3].
It is likely that prescribing PD in each patient with uraemic
toxins as the treatment marker will contribute to reducing
medical costs and improving the QOL.